This profile has not been claimed and data may not be accurate.
Founder108
52nd percentile
Investor0
YC S14First-Time FounderUnicorn FounderIPO500+ EmployeesTop 100k Web
Founder Matrix
Most Complimentary
Credibility
this founder typical founder (50th pct)
GTM / Distribution · 98th percentile
- Ginkgo Bioworks (ginkgo.bio) is ranked 75,028 in the Majestic Million, earning a founder domain bonus.
- Identified Hacker News account @ache linked to Austin Che via keybase proof in bio.
- Ginkgo Bioworks is listed in the Majestic Million at rank 75,028, reflecting significant web presence for the company Austin Che co-founded.
Founder score
- 98%Probability of being accurate (98%)Current founder of Ginkgo Bioworks, active since January 2008.
- 95%Probability of being accurate (95%)Ginkgo Bioworks went public via IPO in 2021 at a $15B valuation.
- 95%Probability of being accurate (95%)Ginkgo Bioworks was co-founded with Jason Kelly, Reshma Shetty, and Barry Canton.
- 92%Probability of being accurate (92%)Y Combinator Summer 2014 alum via Ginkgo Bioworks.
- 88%Probability of being accurate (88%)GitHub account is dormant: no public push in over 9 years (last push was to 'datamatrix' repo).
- 85%Probability of being accurate (85%)GitHub account is over 5 years old, created in July 2012.
- 82%Probability of being accurate (82%)Ginkgo Bioworks (ginkgo.bio) is ranked 75,028 in the Majestic Million, earning a founder domain bonus.
- 82%Probability of being accurate (82%)Ginkgo Bioworks is listed in the Majestic Million at rank 75,028, reflecting significant web presence for the company Austin Che co-founded.
- 80%Probability of being accurate (80%)GitHub account @austinche confirmed as Austin Che's account via name match.
- 72%Probability of being accurate (72%)Identified Hacker News account @ache linked to Austin Che via keybase proof in bio.
- 65%Probability of being accurate (65%)Identified as a researcher on OpenAlex with an h-index of 4 and 58 citations across 17 works.
Investor score
No signal on this dimension.
What you likely need
Austin Che is a high-credibility biotech founder who co-built Ginkgo Bioworks from an MIT lab to a public company worth $15B — a rare and defining achievement. His current focus on strategic partnerships and the Ginkgo ecosystem positions him well for his next chapter, whether that's a new venture, a board role, or a deeper move into investing. Strengthening his public technical presence (GitHub, writing, speaking) would amplify his already strong founder brand.
Are these your current priorities?
We will tune and customize your Founder Festival experience to make sure you get invited to the events that would be most valuable to you.
- positioningActively publicize your Ginkgo IPO experience in founder communities and media — very few founders have taken a biotech from MIT lab to $15B public company and your story is highly differentiated.
- introsConsider formalizing an angel investing practice or joining a biotech-focused syndicate — your domain expertise in synthetic biology and your network from Ginkgo make you a uniquely credible backer for early-stage biotech founders.
- tacticalReactivate your GitHub presence with open-source tooling related to lab automation or synthetic biology — your account has been dormant for 9 years and shipping public code would reinforce your technical credibility.
- introsRe-engage with the Y Combinator alumni network as a mentor or advisor for biotech and deep-tech founders — your S14 batch experience and IPO outcome make you one of the most valuable mentors in that ecosystem.
- fundraisingIf you're considering founding a new company, now is an ideal time — your post-IPO credibility, MIT network, and biotech expertise would make fundraising significantly easier than your first time.
- positioningStart writing publicly about autonomous labs, AI-driven biology, or the future of bioengineering — you have a front-row seat to one of the most important technology transitions and your voice would attract top talent and partners.
- introsPursue board seats at growth-stage biotech or synthetic biology companies — your operational experience across software, finance, people ops, and strategy at Ginkgo is rare and highly valued at the board level.